MUSK and myasthenia gravis: MuSK-MG subjects with prior rituximab treatment showed a moderate but insignificant negative correlation (r= -0.54, p=0.27) (Supplementary Figure 2A), suggesting that DN3 expansion is intrinsic to MuSK-MG pathology rather than a treatment-related effect.